Drug Profile
Research programme: prostaglandin F2 alpha receptor antagonists - ObsEva
Alternative Names: AS-604872; OBE 002Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Merck Serono; ObsEva
- Class Biphenyl compounds; Small molecules; Sulfonamides; Thiazolidines
- Mechanism of Action Prostaglandin F2 alpha antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dysmenorrhoea; Preterm labour
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Dysmenorrhoea in Switzerland (PO)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Preterm-labour in Switzerland (PO)
- 30 Oct 2014 Discontinued - Preclinical for Preterm labour in USA (PO)